Cognition Therapeutics Statistics
Total Valuation
CGTX has a market cap or net worth of $17.66 million. The enterprise value is -$3.77 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, before market open.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CGTX has 40.13 million shares outstanding. The number of shares has increased by 25.67% in one year.
| Current Share Class | 40.13M |
| Shares Outstanding | 40.13M |
| Shares Change (YoY) | +25.67% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 10.62% |
| Float | 33.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.11 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,014.90 |
Financial Efficiency
Return on equity (ROE) is -157.90% and return on invested capital (ROIC) is -163.32%.
| Return on Equity (ROE) | -157.90% |
| Return on Assets (ROA) | -110.08% |
| Return on Capital (ROIC) | -163.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.22M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.28% in the last 52 weeks. The beta is 1.34, so CGTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | -57.28% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 1.40 |
| Relative Strength Index (RSI) | 41.20 |
| Average Volume (20 Days) | 476,735 |
Short Selling Information
The latest short interest is 815,696, so 2.03% of the outstanding shares have been sold short.
| Short Interest | 815,696 |
| Short Previous Month | 490,695 |
| Short % of Shares Out | 2.03% |
| Short % of Float | 2.40% |
| Short Ratio (days to cover) | 1.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -58.43M |
| Pretax Income | -31.08M |
| Net Income | -34.27M |
| EBITDA | -58.33M |
| EBIT | -58.43M |
| Earnings Per Share (EPS) | -$0.95 |
Full Income StatementBalance Sheet
The company has $22.01 million in cash and $580,000 in debt, giving a net cash position of $21.43 million or $0.53 per share.
| Cash & Cash Equivalents | 22.01M |
| Total Debt | 580,000 |
| Net Cash | 21.43M |
| Net Cash Per Share | $0.53 |
| Equity (Book Value) | 14.48M |
| Book Value Per Share | 0.35 |
| Working Capital | 14.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.55 million and capital expenditures -$33,000, giving a free cash flow of -$25.58 million.
| Operating Cash Flow | -25.55M |
| Capital Expenditures | -33,000 |
| Free Cash Flow | -25.58M |
| FCF Per Share | -$0.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |